PEPTIDE GUIDE

What Is Oxytocin?

Oxytocin is a nine-amino-acid peptide hormone and signalling molecule made naturally in the human body. It is best established for two reproductive functions: helping the uterus contract during labour and triggering milk ejection during breastfeeding. A synthetic form is also a long-established prescription medicine used in carefully monitored obstetric care.

Oxytocin has another, more complicated identity in popular culture. It is often called the “love hormone”, “bonding hormone” or “trust hormone”. Those labels are memorable but scientifically weak. Oxytocin participates in networks that process social cues, stress, attachment and threat. Its effects depend on the person, situation, dose, route, timing and outcome being measured. It does not simply create love or trust.

That separation matters because three subjects are frequently blurred together: oxytocin produced inside the body, regulated oxytocin injection used by clinicians, and experimental intranasal products studied for behavioural or psychiatric effects. Evidence for one cannot automatically be transferred to another.

Research statusEstablished obstetric medicine; behavioural uses remain experimental
Compound typeEndogenous cyclic nonapeptide hormone
Human evidenceExtensive obstetric evidence; mixed behavioural evidence
ApprovalApproved medicine for defined obstetric uses
Last reviewedSeptember 2026
THE SHORT ANSWER

Oxytocin is a cyclic nonapeptide, meaning a ring-shaped peptide containing nine amino acids. The hypothalamus produces it, and the posterior pituitary releases much of the circulating hormone. Its clearest physiological roles are uterine contraction and milk ejection. Synthetic oxytocin is an established medicine for defined obstetric indications, but it can cause serious harm if uterine activity, fluid balance and fetal response are not monitored. Intranasal oxytocin has been widely studied in social behaviour, autism, schizophrenia and other conditions, yet findings are mixed and it is not a general treatment for bonding, anxiety or social difficulty. Online “oxytocin peptide” products should not be treated as equivalent to a regulated medicine or a clinical-trial preparation.

What kind of molecule is oxytocin?

Oxytocin consists of nine amino acids: cysteine, tyrosine, isoleucine, glutamine, asparagine, cysteine, proline, leucine and glycinamide. A disulphide bond joins the two cysteine residues, creating a six-amino-acid ring with a short three-residue tail. The amidated end and disulphide bridge are part of the biologically active structure.

It is closely related to arginine vasopressin, another nine-amino-acid hormone. The two human peptides differ at only two positions. This similarity helps explain why selectivity is not absolute. At sufficiently high concentrations, oxytocin can interact with vasopressin receptors, while vasopressin can interact with the oxytocin receptor. Such cross-reactivity is relevant to water balance, cardiovascular effects and the interpretation of laboratory experiments.

Calling oxytocin a peptide is accurate, but it does not make every peptide-labelled product interchangeable. Biological activity depends on the correct sequence, disulphide bridge, terminal chemistry, purity, concentration and formulation. The regulated injectable medicine is a finished sterile drug product. A research vial or nasal product carrying the same name is not automatically the same material.

How was oxytocin discovered and developed?

The story began with observations that extracts from the posterior pituitary could alter uterine activity and blood pressure. In the early twentieth century, researchers separated uterine-contracting and antidiuretic effects conceptually, although the responsible peptides had not yet been fully characterised.

Vincent du Vigneaud and colleagues determined oxytocin’s structure and reported its synthesis in the 1950s. This was a landmark in peptide chemistry because it connected an exact amino-acid sequence and disulphide arrangement with biological activity. Du Vigneaud received the 1955 Nobel Prize in Chemistry for work on biochemically important sulphur compounds, with oxytocin central to that achievement.

Synthetic production replaced reliance on animal posterior-pituitary extracts and allowed a more defined medicine. Clinical obstetrics subsequently accumulated decades of experience with oxytocin for selected labour and postpartum indications. That long history should not be confused with proof for newer intranasal or behavioural uses. The molecule is the same in sequence, but route, exposure, target tissue and clinical question are different.

The history also illustrates why peptide identity alone is not enough. Early extraction, chemical synthesis, modern manufacturing and experimental nasal delivery can all involve oxytocin, yet they do not produce interchangeable evidence packages.

Where is oxytocin made and released?

Oxytocin is synthesised mainly in magnocellular neurons within the paraventricular and supraoptic nuclei of the hypothalamus. The initial gene product is a larger precursor containing oxytocin and its carrier protein, neurophysin I. Processing packages them into secretory vesicles.

Axons from these neurons extend to the posterior pituitary. Electrical activity causes oxytocin to enter the bloodstream from nerve terminals there. This is the classic neuroendocrine pathway. Oxytocin is also released from dendrites and other neuronal compartments within the brain, where it can act as a neuromodulator.

Peripheral and central release are related but not identical. A blood concentration does not provide a simple reading of oxytocin activity at a particular brain circuit. Central release can have different timing and regulation from pituitary release, while measurement in blood, saliva or urine presents technical problems. Claims that a single peripheral test reveals someone’s capacity for attachment or trust therefore go far beyond the evidence.

Oxytocin and oxytocin-receptor expression have also been reported in tissues outside the hypothalamic-pituitary system. The significance varies by tissue, physiological state and method. Detection of a transcript or receptor does not by itself prove a clinically meaningful action.

How does the oxytocin receptor work?

The oxytocin receptor, abbreviated OXTR, is a G-protein-coupled receptor. When oxytocin binds, the receptor can activate intracellular pathways involving phospholipase C, inositol trisphosphate and calcium. In uterine smooth muscle, the rise in intracellular calcium supports contraction.

Receptor signalling is not a single fixed switch. OXTR can couple to different G proteins and signalling pathways according to cell type, receptor density and local conditions. Receptors can also become less responsive after sustained stimulation. The biological result therefore depends on more than the amount of circulating peptide.

During late pregnancy, uterine oxytocin-receptor expression rises substantially under hormonal and mechanical influences. This helps the uterus become more responsive around labour. Local prostaglandin production and electrical coordination between muscle cells also contribute. Oxytocin is important, but labour cannot be reduced to one hormone acting alone.

In the mammary gland, oxytocin receptors on myoepithelial cells help contract the cellular network surrounding milk-producing alveoli. This pushes milk into ducts. Milk production itself is regulated mainly by prolactin; oxytocin primarily supports milk ejection. The two processes are related but different.

How quickly is oxytocin cleared?

Circulating oxytocin is short lived. Product information commonly describes a plasma half-life measured in minutes rather than hours. Enzymatic breakdown occurs in the liver, kidneys and other tissues, and placental oxytocinase activity is relevant during pregnancy.

A short plasma half-life allows clinicians to adjust an intravenous infusion and observe changes in uterine activity, but clinical response does not cease at an exact stopwatch time. Distribution, receptor activation, uterine state and the infusion already delivered all affect what happens next.

Endogenous secretion is pulsatile. A brief burst can convey information differently from a continuous exposure, even if an average concentration appears similar. This helps explain why replacing physiology with a steady external concentration may change receptor response and downstream signalling.

Intranasal pharmacokinetics are harder to describe. Some administered material may be swallowed, some absorbed across nasal tissue and some cleared locally. Blood concentrations and behavioural testing are sampled on different schedules across studies. A nominal spray amount is therefore not a direct measure of concentration at a brain receptor.

What does oxytocin do during labour?

Oxytocin promotes rhythmic contraction of uterine smooth muscle. Stretching of the cervix and lower reproductive tract can increase neural input to oxytocin-producing neurons, which can intensify release and contraction. This positive-feedback process is often called the Ferguson reflex.

Human labour is more complex than a textbook feedback loop. Changes in progesterone signalling, oestrogen action, prostaglandins, inflammatory mediators, uterine stretch, fetal signals and cervical remodelling all contribute. Circulating oxytocin does not necessarily rise dramatically before labour begins. Increased receptor expression and pulsatile release may be as important as a simple change in average concentration.

Synthetic oxytocin can initiate or strengthen uterine contractions when clinicians judge this medically appropriate. Because excessive stimulation can reduce the recovery time between contractions, administration requires observation of contraction patterns and fetal response. More contraction is not automatically better. The clinical aim is effective labour with acceptable maternal and fetal safety.

What does oxytocin do after birth?

After delivery, sustained contraction of the uterus helps compress blood vessels at the placental site. Poor uterine contraction, known as uterine atony, is a major cause of postpartum haemorrhage. Oxytocin is therefore used internationally as a uterotonic medicine to prevent or treat bleeding in appropriate settings.

The World Health Organization recommends an effective uterotonic during the third stage of labour for prevention of postpartum haemorrhage, with oxytocin preferred where several options are available and its quality can be assured. NICE guidance also includes oxytocin within active management and treatment pathways. These are clinical protocols, not instructions for unsupervised administration.

Storage and supply quality matter in global health. Oxytocin is a peptide and can lose potency when exposed to unsuitable heat over time. A labelled ampoule that has degraded may deliver less active medicine than expected. This is one reason procurement, cold-chain practice and validated stability are part of medicine quality.

How does the milk-ejection reflex work?

Sensory stimulation of the nipple during feeding sends neural signals to the hypothalamus. Oxytocin neurons respond in coordinated bursts, and circulating oxytocin causes myoepithelial cells in the breast to contract. Milk is moved towards the nipple, producing the let-down or milk-ejection reflex.

This does not mean oxytocin alone determines breastfeeding success. Milk supply, infant latch, feeding frequency, breast anatomy, maternal pain, illness, medicines and support all matter. Stress and pain can interfere with reflexes, but reducing every breastfeeding problem to “low oxytocin” is not justified.

Oxytocin is sometimes discussed as a treatment for breastfeeding difficulty. Historical and small studies have examined nasal preparations, yet routine claims require caution. A measurable hormonal action is not the same as proof that a marketed nasal spray improves meaningful feeding outcomes. Clinical assessment should address the actual cause of difficulty.

Is oxytocin really the love hormone?

The phrase arose because oxytocin systems are involved in maternal behaviour, pair bonding and social recognition in several animal models, and because human studies linked oxytocin administration or endogenous measures with aspects of trust and social interaction. The label turns a context-dependent signalling system into a simple emotional switch.

Human social behaviour is not organised by one molecule. Oxytocin may change the salience of social cues, attention to faces, memory for social information or responses to members of one’s own group. Under some conditions, increased attention to social information could support affiliation. Under others, it could intensify anxiety, defensiveness, envy or sensitivity to threat.

Early experiments were often small and tested many behavioural outcomes. Some influential findings were difficult to reproduce or produced smaller effects in later work. Publication bias, flexible analysis, participant differences and uncertainty about intranasal delivery all complicate the literature.

The careful conclusion is that oxytocin contributes to social and emotional processing. It does not compel trust, create attachment on demand or reveal the quality of a relationship. “Love hormone” is a cultural nickname, not a clinical description.

What is intranasal oxytocin research trying to achieve?

Intranasal administration has been used in research partly because oxytocin taken by mouth would be broken down in the gastrointestinal tract and has poor systemic bioavailability. Nasal delivery can produce peripheral exposure and may allow some peptide or downstream signal to affect the central nervous system. The precise routes and amounts reaching relevant human brain regions remain debated.

Researchers have tested acute changes in social cognition, emotion recognition, memory, stress response, pain and interpersonal behaviour. Clinical programmes have examined autism spectrum disorder, schizophrenia, social anxiety, depression, post-traumatic stress and other conditions.

Results are heterogeneous. Meta-analyses sometimes identify small effects in selected domains, but pooled results depend on which studies, populations and outcomes are included. A change on one laboratory task does not establish improvement in daily functioning. Acute experiments in healthy volunteers do not establish durable treatment effects in people with a diagnosed condition.

Nasal devices, spray deposition, nasal anatomy and formulation can alter exposure. Studies also differ in timing, amount, frequency, participant sex, hormonal status and social context. These sources of variation make a universal “oxytocin effect” unlikely.

What has research found in autism?

Autism studies have examined whether intranasal oxytocin improves social communication, social attention or repetitive behaviour. Trials have varied greatly in age, duration, outcome selection and study size. Some small studies reported improvements in particular measures, while others did not find a meaningful advantage over placebo.

Meta-analyses have reached qualified and sometimes differing conclusions. Even when a pooled social-functioning effect is reported, heterogeneity and small-study limitations affect confidence. There is no basis for presenting intranasal oxytocin as a proven general treatment for autism.

Autism is also not simply a deficiency of sociability or oxytocin. It is a heterogeneous neurodevelopmental condition. Outcomes chosen by researchers may not reflect the priorities of autistic people, such as wellbeing, communication on their own terms and relief from distress. Biological plausibility should not replace patient-relevant evidence.

What has research found in schizophrenia and other psychiatric conditions?

Schizophrenia research has focused particularly on social cognition and negative symptoms. Meta-analytic work has suggested possible effects in some higher-level social-cognitive tasks while failing to show broad improvement across social cognition or neurocognition. Results should be read as exploratory rather than as evidence for established treatment.

The same restraint applies to anxiety, trauma-related conditions and depression. Oxytocin can interact with stress and salience systems, but the direction of effect may depend on baseline anxiety, attachment pattern, trauma history and whether the environment feels safe. A mechanism that heightens attention to social cues could help in one context and worsen distress in another.

No broad psychiatric indication follows merely from evidence that a peptide changes brain activity or performance on a task. Treatment requires replicated clinical benefit, acceptable safety, suitable formulation and regulatory assessment.

Why are behavioural oxytocin studies difficult to interpret?

Behavioural experiments face several layers of uncertainty at once. A study may recruit a small, homogeneous group, administer one intranasal session and then test multiple ratings, reaction times or facial-expression tasks. Testing many outcomes increases the chance of a nominally positive result unless the analysis controls for multiplicity.

Blinding can also be imperfect if participants notice nasal irritation or expect a particular emotional response. Social tasks may behave differently across laboratories, languages and cultures. A statistically significant average can hide people moving in opposite directions.

Replication is especially important because context can modify the outcome. Familiarity with the other person, perceived threat, baseline social anxiety and group membership may all matter. A result in healthy young men cannot automatically be applied to women, children, older adults or a clinical population.

Preregistration, adequate sample size, standardised administration, direct replication and patient-relevant outcomes can improve confidence. Biomarkers and brain imaging can add mechanistic information, but they do not replace evidence that people function or feel better in daily life.

Does intranasal oxytocin reach the brain?

The honest answer is that intranasal dosing can affect human physiology and behaviour, but the route from nose to a specific brain target is not completely resolved. Possible paths include absorption into the bloodstream, entry along olfactory or trigeminal pathways, effects on peripheral receptors that signal centrally, or stimulation of endogenous oxytocin systems.

Measuring oxytocin is itself difficult. Immunoassays can vary depending on extraction and interference, and peripheral samples may not reflect synaptic release. An increase in blood or saliva after a nasal dose cannot prove that a therapeutically relevant amount reached a particular brain circuit.

This uncertainty does not mean every intranasal finding is false. It means mechanistic claims should be narrower than the observed data. If a trial records a behavioural difference after administration, that result supports an effect under the study conditions. It does not by itself establish direct nose-to-brain delivery or explain the pathway.

What are the approved medical uses of oxytocin?

Regulatory wording varies by country and product. US prescribing information for oxytocin injection includes medically indicated initiation or improvement of uterine contractions, reinforcement of labour in selected cases and adjunctive management of incomplete or inevitable abortion. Products are also used after delivery to produce uterine contractions and control postpartum bleeding.

In the UK, oxytocin products are authorised for defined obstetric uses under professional supervision. Local product information and clinical guidelines determine the indication, preparation, route, monitoring and response to complications.

Approval is specific to the finished medicinal product. It does not mean that any oxytocin sold online is approved, that intranasal oxytocin is approved for behavioural enhancement, or that a research vial can substitute for an injectable medicine.

Why does clinical oxytocin require close monitoring?

The most immediate risk during labour is uterine tachysystole or hyperstimulation, meaning contractions that are too frequent, too prolonged or insufficiently separated. This can impair fetal oxygenation, cause abnormal fetal heart-rate patterns and, in severe cases, contribute to uterine injury or rupture.

Oxytocin also has antidiuretic activity, partly because of structural similarity to vasopressin. Prolonged administration with large amounts of electrolyte-free fluid can contribute to water intoxication and hyponatraemia. Severe cases may cause headache, confusion, seizures, coma or death.

Other reported maternal reactions include nausea, vomiting, cardiovascular changes, arrhythmias, bleeding complications and hypersensitivity reactions. Fetal or newborn consequences can arise from excessive uterine activity and altered oxygen delivery. Risk depends on obstetric circumstances, co-administered medicines and the way treatment is managed.

These risks explain why prescribing information calls for trained personnel, observation and control of infusion. The existence of an endogenous hormone does not make concentrated synthetic administration inherently gentle.

What is known about intranasal safety?

Short research studies often report mild effects such as nasal irritation, headache, tiredness or transient discomfort, and many record no major difference from placebo. That does not settle long-term safety. Study populations are frequently small, exposure is limited and uncommon adverse effects are difficult to detect.

Oxytocin can affect reproductive, cardiovascular, fluid-balance and social-processing systems. Safety conclusions from a single dose in healthy volunteers cannot be extended automatically to repeated unsupervised use, pregnancy, cardiovascular disease, psychiatric illness or combination with other medicines.

Product quality adds a separate risk. An unregulated nasal spray may contain the wrong concentration, degraded peptide, impurities, microbial contamination or a different compound. Preservatives and delivery devices can also affect tolerability and exposure.

How is pharmaceutical oxytocin manufactured?

Modern synthetic oxytocin can be assembled by chemical peptide synthesis. Protected amino acids are joined in the correct order, commonly on a solid support. After chain assembly and cleavage, controlled oxidation forms the disulphide bond that closes the ring. The C-terminal glycine is amidated in the active molecule.

The crude product may contain shortened sequences, incorrectly linked material, oxidation products, residual solvents and other process-related impurities. Purification commonly uses chromatography. Identity and structure can be assessed using mass spectrometry, chromatographic retention, amino-acid analysis and other orthogonal tests.

Manufacturing the active peptide is only part of making an injectable medicine. The final product needs validated content and potency, sterility, bacterial-endotoxin control, particulate testing, pH and container-closure integrity. Stability studies must show how the product behaves under labelled storage conditions.

Oxytocin can undergo deamidation, oxidation, disulphide exchange and aggregation. Heat and unsuitable pH can accelerate degradation. A chromatogram showing a large main peak does not establish sterile manufacture, correct potency or stability throughout transport.

Why do storage and formulation matter?

Peptides exist in equilibrium with their surroundings. Buffer composition, pH, oxygen, light, trace metals, surfaces and temperature can all affect oxytocin over time. A manufacturer chooses formulation conditions and packaging using stability studies rather than assuming that dry or refrigerated material will remain unchanged indefinitely.

Loss of potency is particularly important for an obstetric medicine used to prevent or control bleeding. Global-health programmes have examined heat exposure and supply-chain quality because a degraded product may look normal. Visual inspection cannot demonstrate molecular integrity.

Freezing is not automatically protective. Freeze-thaw stress can alter a formulation, and a container may not have been validated for it. Repeated warming and cooling can also add cumulative stress. The labelled storage conditions of the exact regulated product are the relevant standard.

For unregulated material, storage instructions cannot repair unknown manufacture. Even ideal temperature control does not establish identity, starting purity, sterility or content.

How is oxytocin measured in research?

Researchers use immunoassays and increasingly mass-spectrometry-based approaches, but oxytocin measurement remains technically demanding. Concentrations can be low, sample handling matters and proteins or other matrix components can interfere.

Whether samples are extracted before immunoassay can materially affect results. Different assays may produce values that are not directly comparable. Pulsatile release also means that a single time point can miss dynamic change.

Salivary and urinary measurements are attractive because collection is easier, but their relationship to central oxytocin activity is not straightforward. Studies linking one peripheral measurement with a complex trait should therefore be interpreted cautiously, especially when sample sizes are small or many correlations are tested.

What is the difference between oxytocin, carbetocin and vasopressin?

MoleculeBasic descriptionImportant difference
OxytocinEndogenous cyclic nine-amino-acid hormone and synthetic medicineShort acting and used in defined obstetric settings
CarbetocinLonger-acting synthetic oxytocin analogueDifferent structure, exposure and approved uses; not interchangeable dose for dose
VasopressinClosely related endogenous nonapeptidePrincipally regulates water balance and vascular tone through vasopressin receptors

Structural similarity does not make these molecules substitutes. Receptor selectivity, half-life, formulation and clinical evidence differ. Product-specific information should guide medical use.

Does oxytocin affect men as well as women?

Yes. People of all sexes produce oxytocin and express oxytocin receptors. Research in men has examined social cognition, stress, sexual function, parental responses and other outcomes. Oxytocin is not a “female-only” hormone.

Its established obstetric uses obviously concern pregnancy and birth, and milk ejection concerns lactation. Those prominent roles should not be confused with exclusive production. Sex hormones, reproductive state and individual biology may modify responses, which is another reason not to generalise from one small study population.

Does oxytocin increase testosterone, libido or sexual performance?

Oxytocin participates in sexual physiology and has been studied in arousal, orgasm, pair interaction and reproductive-tract function. This does not establish it as a reliable testosterone booster or sexual-performance treatment.

Small experimental findings and mechanistic observations are often amplified into commercial claims. A meaningful treatment claim would require controlled trials using relevant clinical outcomes, a defined product and an acceptable safety profile. Evidence for one aspect of sexual response cannot be converted into a general claim about libido, fertility or relationship quality.

Can oxytocin improve trust, empathy or relationships?

There is no dependable basis for using oxytocin as a chemical shortcut to trust or intimacy. Laboratory tasks measure narrow responses under controlled conditions. Real relationships involve history, consent, communication, learning and social context.

Some research suggests oxytocin may increase attention to socially relevant information rather than producing uniformly prosocial behaviour. If the cue is threatening or the context competitive, increased salience may not feel warm or trusting.

There is also an ethical difference between studying a hormone and using it to influence another person. Covert or coercive administration would be unsafe and unacceptable regardless of whether the hoped-for behavioural effect is scientifically plausible.

What remains uncertain?

Important uncertainties include how peripheral and central oxytocin systems interact, which intranasal delivery mechanisms matter, whether any psychiatric subgroup obtains durable benefit, and how repeated exposure changes receptor responsiveness.

The field also needs larger preregistered studies, harmonised outcomes, better exposure measurements and stronger replication. Sex, hormonal state, trauma history, genetics and social context may all influence response, but subgroup findings can be unreliable when studies are small.

For established obstetric uses, uncertainty is different. Oxytocin clearly has clinical effects, but the safest regimen and comparative choice can depend on the indication, setting, monitoring resources and patient characteristics. Guidelines evolve as evidence changes.

FREQUENTLY ASKED QUESTIONS

Frequently asked questions

Is oxytocin a peptide?

Yes. It is a cyclic peptide containing nine amino acids.

Is oxytocin naturally present in the body?

Yes. It is produced mainly by hypothalamic neurons and released both into the bloodstream and within neural circuits.

What are its best-established natural functions?

Uterine contraction around childbirth and milk ejection during breastfeeding are the clearest established functions.

Is synthetic oxytocin an approved medicine?

Yes. Regulated injectable products are approved for defined obstetric uses. Exact indications and labelling vary by jurisdiction and product.

Is intranasal oxytocin approved for autism or social anxiety?

No general approval is established for those uses. Intranasal oxytocin remains experimental in behavioural and psychiatric research.

Does oxytocin make people fall in love?

No. It influences aspects of social and emotional processing but does not create love, loyalty or trust on command.

Does hugging release oxytocin?

Affiliative contact has been associated with oxytocin-system activity in some studies, but peripheral measurements are difficult to interpret and responses vary. This does not turn a specific behaviour into a precise hormonal dose.

Is more oxytocin always better?

No. Biological effects are context dependent. In obstetric medicine, excessive stimulation can be dangerous.

Can oxytocin be taken by mouth?

Ordinary oral delivery is unsuitable for reliable systemic peptide exposure because digestion and poor absorption limit intact oxytocin. This does not validate unapproved alternative formulations.

Does a nasal spray deliver oxytocin directly to the brain?

Intranasal administration can produce biological effects, but the amount and route reaching particular brain regions remain uncertain.

Is oxytocin the same as vasopressin?

No. They are closely related nine-amino-acid hormones with overlapping receptor pharmacology, but they have different principal physiological roles.

Is oxytocin safe because the body makes it?

No. Concentrated administration can produce effects far beyond normal local and pulsatile release. Injectable oxytocin has important contraindications and risks.

Are research products equivalent to hospital oxytocin?

No. The name does not establish pharmaceutical identity, concentration, sterility, stability or regulatory approval.

Can oxytocin be used without medical supervision during pregnancy?

No. Obstetric oxytocin requires professional assessment and monitoring because inappropriate use can harm the pregnant person and fetus.

RESEARCH AND MEDICAL NOTICE

This guide explains oxytocin biology, approved medical context and published research. It does not provide personal medical advice, recommend an oxytocin product, describe self-administration or suggest using oxytocin to influence another person.

RESEARCH LIBRARY

Sources

Regulatory and clinical guidanceDailyMed
DailyMed oxytocin injection labelOpen source →
Regulatory and clinical guidancewho.int
WHO uterotonics for postpartum haemorrhage preventionOpen source →
Regulatory and clinical guidancewho.int
WHO recommendation on oxytocin administration routesOpen source →
Regulatory and clinical guidancenice.org.uk
NICE intrapartum care recommendationsOpen source →
Biology and pharmacologyPubMed
The oxytocin receptor: signalling to behaviourOpen source →
Biology and pharmacologyPubMed
Central and peripheral release of oxytocinOpen source →
Biology and pharmacologyPubMed
Oxytocin signalling pathway reviewOpen source →
Biology and pharmacologyPubMed
Is oxytocin “nature’s medicine”?Open source →
Intranasal and behavioural evidencePubMed
Statistical and methodological considerationsOpen source →
Intranasal and behavioural evidencePubMed
Intranasal oxytocin effects: a critiqueOpen source →
Intranasal and behavioural evidencePubMed
Publication bias in behavioural oxytocin researchOpen source →
Intranasal and behavioural evidencePubMed
Systematic review of psychosocial outcomesOpen source →
Intranasal and behavioural evidencePubMed
Neurodevelopmental-disorder meta-analysisOpen source →
Intranasal and behavioural evidencePubMed
Autism multilevel meta-analysisOpen source →
Intranasal and behavioural evidencePubMed
Schizophrenia Bayesian meta-analysisOpen source →
Intranasal and behavioural evidenceClinicalTrials.gov
ClinicalTrials.gov search for intranasal oxytocinOpen source →

Research reviewed through September 2026.